Clinical trials: Walking
Pulmonary Disease, Chronic Obstructive
Six-Minute Walk Test Comparing Helium/Oxygen to Nitrogen/Oxygen for COPD Rehabilitation
The purpose of this study is to evaluate effects of inspired gas mixtures on the distance walked by patients with severe Chronic Obstructive Pulmonary Disease (COPD) during a Six-Minute Walk test.
- Trial name
- rehabilitate (NCT01355809)
- Testing
- Inhalation gas, Inhalation Nitrogen/Oxygen, Inhalation Helium/Oxygen
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Air Liquide SA
Breast Cancer, Fatigue
The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older
This multicenter randomized (1:1) phase 2 study is designed to assess the efficacy of the Walk with Ease exercise program on improving fatigue after adjuvant radiotherapy compared to usual care in 50 women with stage 0-3 breast…
- Trial name
- WWE (NCT02434367)
- Testing
- Walk With Ease Arm A
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- The West Clinic, Memphis
Chronic Obstructive Pulmonary Disease
A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the safety and preliminary performance of the ROX Anastomotic Coupler System (ACS), with standard of care (as defined per GOLD) in patients with Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT00992680
- Testing
- ROX Anastomotic Coupler System (ACS)
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- ROX Medical, Inc.
Intermittent Claudication
Clinical Trial for GNX80 in Intermittent Claudication
This is a Phase 4, randomized clinical trial to evaluate whether GNX80 vs. placebo, prescribed for 6 months to patients with Intermittent Claudication(IC) would lead to an improvement in the walking distance.
- Trial name
- NCT05400395
- Testing
- GNX80
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- SK Chemicals Co., Ltd.
Idiopathic Pulmonary Fibrosis
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg…
- Trial name
- NCT01979952
- Testing
- Nintedanib
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who…
- Trial name
- NCT00648908
- Testing
- Fampridine-SR
- Where
- 32 sites in United States, Canada
- Volunteers
- 269 people
- Sponsor
- Acorda Therapeutics
Neuropathy (Disorder)
Contribution of an Off-the-shelf Carbon Ankle Foot Orthosis (AFO) in the Management of Walking Functional Impairment
The objective of this study is to assess the superiority in achieving personal goals (set by the patient and the medical team) according to the GAS scale (Goal Attainment Scaling) while wearing the carbon medical device Ankle…
- Trial name
- DEFISTEP (NCT05131399)
- Testing
- Phase A1, Phase B1, Phase A2
- Where
- 8 sites in France
- Volunteers
- 20 people
- Sponsor
- Thuasne
Injuries, Spinal Cord
The WISE Trial - Walking Improvement for SCI With Exoskeleton
A randomized, controlled trial comparing exoskeleton gait training with standard gait training or no gait training in community-dwelling participants with chronic incomplete spinal cord injury
- Trial name
- WISE (NCT02943915)
- Testing
- Ekso GT Rehabilitation Therapy, Body Weight Supported (BWS) Treadmill Training
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ekso Bionics
Peripheral Vascular Diseases
Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
The purpose of this study is to assess the safety and the immediate effect of the VascuActive device on patients with peripheral vascular disease and limb ischemia.
- Trial name
- NCT01014377
- Testing
- VascuActive
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- VascuActive LTD
Lymphangioleiomyomatosis
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis
- Trial name
- NCT01059318
- Testing
- Everolimus
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Intermittent Claudication, Peripheral Vascular Disease
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries.
- Trial name
- NCT00071266
- Testing
- Niacin Extended Release and Lovastatin Tablets
- Where
- 26 sites in United States
- Volunteers
- 870 people
- Sponsor
- Kos Pharmaceuticals
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Intermittent Claudication, Peripheral Vascular Disease
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses, compared to diet control (this group will receive a tablet containing 50 mg.
- Trial name
- NCT00062556
- Testing
- Niacin Extended Release and Lovastatin Tablets
- Volunteers
- 366 people
- Sponsor
- Kos Pharmaceuticals
Fracture Healing, Treatment Duration
Smart Crutch Tips for Guided Weight-Bearing in Patients Recovering From Extra-Articular Distal Tibia Fractures
The goal of this clinical trial is to learn whether personalized weight-bearing prescriptions using Smart Crutch Tips™ can improve recovery after surgery for extra-articular distal tibia fractures.
- Conditions
- Fracture Healing, Treatment Duration, Distal Tibia Fracture
- Trial name
- NCT07138066
- Testing
- Smart Crutch Tips™, Finite Element Analysis (FEA), Iterative walking
- Where
- 18 sites in Ukraine
- Volunteers
- 30 people
- Sponsor
- Comeback Mobility Inc
PAH
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of 2 doses of CXA-10 on stable background therapy in 96 subjects 18 to 80 years of age with PAH.
- Trial name
- PAH (NCT03449524)
- Testing
- 75mg CXA-10, 150mg CXA-10
- Where
- 46 sites in United States, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Complexa, Inc.
Pulmonary Arterial Hypertension
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
This is a multicenter, randomized (2:1 oral treprostinil: placebo), double-blind, placebo-controlled study in subjects with Pulmonary Arterial Hypertension (PAH) who are currently receiving background dual therapy (ambrisentan…
- Trial name
- NCT02999906
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension
This is an open-label, multicenter, parallel, randomized (1:1 Slow Dose Titration Group; Rapid Dose Titration Group), two-group study to evaluate the safety, tolerability, pharmacokinetics and efficacy of slow and rapid dose…
- Trial name
- NCT02893995
- Testing
- Slow Dose Titration Group of Subcutaneous Treprostinil, Rapid Dose Titration Group of Subcutaneous Treprostinil
- Where
- 10 sites in China
- Sponsor
- United Therapeutics
Chronic Stroke
Post-Stroke Walking Speed and Community Ambulation Conversion Study
The purpose of this randomized, controlled study is to collect performance data on the ability of an investigational device designed to digitally deliver Rhythmic Auditory Stimulation to improve walking speed in people who…
- Trial name
- NCT04121754
- Testing
- MR-001, Active Walking
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- MedRhythms, Inc.
Adrenomyeloneuropathy, Adrenoleukodystrophy
MD1003-AMN MD1003 in Adrenomyeloneuropathy
The primary objective of the trial is to demonstrate the superiority of biotin at 300 mg/day over placebo in the clinical improvement (walking tests) of patients with adrenomyeloneuropathy
- Conditions
- Adrenomyeloneuropathy, Adrenoleukodystrophy, AMN
- Trial name
- NCT02961803
- Testing
- MD1003 100 mg capsule
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 67 people
- Sponsor
- MedDay Pharmaceuticals SA